首页> 美国卫生研究院文献>Public Health Ethics >Reasons Why Post-Trial Access to Trial Drugs Should or Need not be Ensured to Research Participants: A Systematic Review
【2h】

Reasons Why Post-Trial Access to Trial Drugs Should or Need not be Ensured to Research Participants: A Systematic Review

机译:为什么应该或不需要确保研究参与者试用药物的原因:系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: researchers and sponsors increasingly confront the issue of whether participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or silent about many aspects of PTA. Recent research highlights the potential importance of systematic reviews (SRs) of reason-based literatures in informing decision-making in medicine, medical research and health policy. Purpose: to systematically review reasons why drug trial participants should, or need not be ensured PTA to the trial drug and the uses of such reasons. Data sources: databases in science/medicine, law and ethics, thesis databases, bibliographies, research ethics books and included publications’ notes/bibliographies. Publication selection: a publication was included if it included a reason as above. See article for detailed inclusion conditions. Data extraction and analysis: two reviewers extracted and analyzed data on publications and reasons. Results: of 2060 publications identified, 75 were included. These mentioned reasons based on morality, legality, interests/incentives, or practicality, comprising 36 broad (235 narrow) types of reason. None of the included publications, which included informal reviews and reports by official bodies, mentioned more than 22 broad (59 narrow) types. For many reasons, publications differed about the reason’s interpretation, implications and/or persuasiveness. Publications differed also regarding costs, feasibility and legality of PTA. Limitations: reason types could be applied differently. The quality of reasons was not measured. Conclusion: this review captured a greater variety of reasons and of their uses than any included publication. Decisions based on informal reviews or sub-sets of literature are likely to be biased. Research is needed on PTA ethics, costs, feasibility and legality and on assessing the quality of reason-based literature.
机译:背景:研究人员和申办者越来越多地面临临床试验参与者是否应具有试验药物的试用后访问权(PTA)的问题。关于PTA的许多方面,法律和指导方针前后矛盾,模棱两可或沉默。最近的研究强调了基于原因的文献的系统评价(SR)在告知医学,医学研究和卫生政策决策方面的潜在重要性。目的:系统地审查为什么应该或不需要确保试验药品的PTA的原因以及此类原因的用途。数据来源:科学/医学,法律和伦理学数据库,论文数据库,书目,研究伦理书籍,并包括出版物的注释/书目。出版物选择:如果出版物包含上述原因,则将其包括在内。有关详细的包含条件,请参见文章。数据提取和分析:两名审稿人提取并分析了有关出版物和原因的数据。结果:在确定的2060种出版物中,包括75种。这些基于道德,合法性,利益/动机或实用性的提及原因,包括36种广泛(235种狭窄)原因。包括官方机构的非正式审查和报告在内的所有出版物均未提及22种以上(59种狭窄)类型。由于许多原因,出版物对原因的解释,含义和/或说服力有所不同。关于PTA的成本,可行性和合法性,出版物也有所不同。局限性:原因类型可以不同地应用。原因的质量无法衡量。结论:与任何随附的出版物相比,本综述涵盖了更多的原因及其用途。基于非正式评论或子集的决策可能会产生偏差。需要就PTA道德,成本,可行性和合法性以及评估基于原因的文献的质量进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号